CAS 1311385-20-2

Fórmula: C10H12N4O4S

InChI: InChI=1S/C10H12N4O4S/c11-10(8(17)18)1-3(19-9-12-2-13-14-9)4-5(6(4)10)7(15)16/h2-6H,1,11H2,(H,15,16)(H,17,18)(H,12,13,14)/t3-,4+,5+,6+,10+/m1/s1

Chave InChI: YSOWRGMLMZQSBX-AVUIYAGVSA-N

SMILES: C1[C@H]([C@H]2[C@@H]([C@H]2[C@@]1(C(=O)O)N)C(=O)O)SC3=NC=NN3

LY2812223

CAS: 1311385-20-2

LY2812223

Fórmula: C₁₀H₁₂N₄O₄S

Pureza: 98%

Peso molecular: 284.29

Ref: 54-OR1114505

LY2812223

CAS: 1311385-20-2

LY2812223: selective mGlu2 agonist; binds mGlu2/mGlu3 (Ki=144/156 nM).

Fórmula: C₁₀H₁₂N₄O₄S

Pureza: 98%

Cor e Forma: Solid

Peso molecular: 284.292

Ref: TM-T15809

LY2812223

CAS: 1311385-20-2

Fórmula: C₁₀H₁₂N₄O₄S

Pureza: 98.0%

Peso molecular: 284.2917

Ref: IN-DA01NO5G

LY2812223

CAS: 1311385-20-2

LY2812223 is a drug that is currently in clinical development. It is a low-potency antagonist of the N-methyl-D-aspartate (NMDA) receptor and it has been shown to be effective in animal models of neurodevelopmental, psychotic, and other disorders. LY2812223 binds reversibly to the NMDA receptor and prevents the ion channel from opening. This drug has not been tested in humans, but it has been shown to have good absorption across the blood brain barrier and does not produce any neurotoxic effects. LY2812223 is being developed for the treatment of schizophrenia, bipolar disorder, major depressive disorder, autism spectrum disorders, and Alzheimer’s disease.
END>>

Fórmula: C₁₀H₁₂N₄O₄S

Pureza: Min. 95%

Peso molecular: 284.29 g/mol

Ref: 3D-LCC38520